{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T23:53:06Z","timestamp":1781481186283,"version":"3.54.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009141","name":"Cancer League of Colorado","doi-asserted-by":"publisher","award":["P30CA046934"],"award-info":[{"award-number":["P30CA046934"]}],"id":[{"id":"10.13039\/100009141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-49566-0","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T07:05:36Z","timestamp":1776755136000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Omacetaxine reduces c-Myc expression and demonstrates antitumor effects in osteosarcoma"],"prefix":"10.1038","volume":"16","author":[{"given":"Kristen B.","family":"Farrell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunetra","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas H.","family":"Thamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"49566_CR1","doi-asserted-by":"publisher","unstructured":"Panez-Toro, I. et al. Advances in Osteosarcoma. Current Osteoporosis Reports,\u00a021, 330\u2013343 (2023). https:\/\/doi.org\/10.1007\/s11914-023-00803-9","DOI":"10.1007\/s11914-023-00803-9"},{"key":"49566_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.780264","author":"G Sheng","year":"2021","unstructured":"Sheng, G., Gao, Y., Yang, Y. & Wu, H. Osteosarcoma and metastasis.\u00a0Front. Oncol.\u00a011:780264. https:\/\/doi.org\/10.3389\/fonc.2021.780264 (2021).","journal-title":"Front. Oncol."},{"key":"49566_CR3","unstructured":"Bone Cancer in Dogs. American Kennel Club Canine Health Foundation (2010). https:\/\/www.akcchf.org\/disease-history\/bone-cancer-in-dogs\/"},{"key":"49566_CR4","unstructured":"About Osteosarcoma. American Cancer Society (2020). https:\/\/www.cancer.org\/content\/dam\/CRC\/PDF\/Public\/8768.00.pdf"},{"key":"49566_CR5","doi-asserted-by":"publisher","unstructured":"Gustafson, D. L., Duval, D. L., Regan, D. P. & Thamm, D. H. Canine sarcomas as a surrogate for the human disease. Pharmacology and Therapeutics. 188, 80\u201396 (2018). https:\/\/doi.org\/10.1016\/j.pharmthera.2018.01.012","DOI":"10.1016\/j.pharmthera.2018.01.012"},{"key":"49566_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1130215","author":"M Klosowski","year":"2023","unstructured":"Klosowski, M. et al. Naturally occurring canine sarcomas: Bridging the gap from mouse models to human patients through cross-disciplinary research partnerships.. Front. Oncol.\u00a013:1130215. https:\/\/doi.org\/10.3389\/fonc.2023.1130215 (2023).","journal-title":"Front. Oncol."},{"key":"49566_CR7","doi-asserted-by":"publisher","unstructured":"McGee, L.E., Pereira, J.S., McEachron, T.A. et al. The tumor microenvironment of metastatic osteosarcoma in the human and canine lung. Commun Biol 8, 756 (2025). https:\/\/doi.org\/10.1038\/s42003-025-07992-2","DOI":"10.1038\/s42003-025-07992-2"},{"key":"49566_CR8","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1158\/1535-7163.MCT-18-1346","volume":"18","author":"S Das","year":"2019","unstructured":"Das, S., Idate, R., Cronise, K. E., Gustafson, D. L. & Duval, D. L. Identifying candidate druggable targets in canine cancer cell lines using whole-exome sequencing. Mol. Cancer Ther. 18, 1460\u20131471 (2019).","journal-title":"Mol. Cancer Ther."},{"key":"49566_CR9","doi-asserted-by":"publisher","unstructured":"Beck, J. et al. Canine and murine models of osteosarcoma. Veterinary Pathology vol. 59 399\u2013414 Preprint at (2022). https:\/\/doi.org\/10.1177\/03009858221083038","DOI":"10.1177\/03009858221083038"},{"key":"49566_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-023-05208-z","author":"JD Mannheimer","year":"2023","unstructured":"Mannheimer, J.D., Tawa, G., Gerhold, D. et al. Transcriptional profiling of canine osteosarcoma identifies prognostic gene expression signatures with translational value for humans. Commun Biol 6, 856 (2023). https:\/\/doi.org\/10.1038\/s42003-023-05208-z","journal-title":"Commun. Biol."},{"key":"49566_CR11","doi-asserted-by":"publisher","unstructured":"Kantarjian, H. M., O\u2019Brien, S. & Cortes, J. Homoharringtonine\/omacetaxine mepesuccinate: The long and winding road to food and drug administration approval. Clinical Lymphoma, Myeloma and Leukemia. 13, 530\u2013533 (2013). https:\/\/doi.org\/10.1016\/j.clml.2013.03.017","DOI":"10.1016\/j.clml.2013.03.017"},{"key":"49566_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40487-018-0058-6","volume":"6","author":"ES Winer","year":"2018","unstructured":"Winer, E. S. & DeAngelo, D. J. A review of omacetaxine: A chronic myeloid leukemia treatment resurrected. Oncol. Ther. 6, 9\u201320 (2018).","journal-title":"Oncol. Ther."},{"key":"49566_CR13","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/0014-5793(89)81546-7","volume":"257","author":"RM Tujebajeva","year":"1989","unstructured":"Tujebajeva, R. M., Graifer, D. M., Karpova, G. G. & Ajtkhozhina, N. A. Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formation. FEBS Lett. 257, 254\u2013256 (1989).","journal-title":"FEBS Lett."},{"key":"49566_CR14","doi-asserted-by":"publisher","unstructured":"Wang, W. et al. Homoharringtonine: mechanisms, clinical applications and research progress. Frontiers in Oncology.\u00a015,\u00a0(2025). https:\/\/doi.org\/10.3389\/fonc.2025.1522273","DOI":"10.3389\/fonc.2025.1522273"},{"key":"49566_CR15","doi-asserted-by":"publisher","unstructured":"Madden, S. K., de Araujo, A. D., Gerhardt, M., Fairlie, D. P. & Mason, J. M. Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc. Molecular Cancer. 20 (2021). https:\/\/doi.org\/10.1186\/s12943-020-01291-6","DOI":"10.1186\/s12943-020-01291-6"},{"key":"49566_CR16","doi-asserted-by":"publisher","unstructured":"Wang, C. et al. Alternative approaches to target Myc for cancer treatment. Signal Transduction and Targeted Therapy. 6,\u00a0(2021). https:\/\/doi.org\/10.1038\/s41392-021-00500-y","DOI":"10.1038\/s41392-021-00500-y"},{"key":"49566_CR17","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1158\/1078-0432.CCR-20-2246","volume":"27","author":"ZJ Walker","year":"2021","unstructured":"Walker, Z. J. et al. Exploiting protein translation dependence in multiple myeloma with omacetaxine-based therapy. Clin. Cancer Res. 27, 819\u2013830 (2021).","journal-title":"Clin. Cancer Res."},{"key":"49566_CR18","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1073\/pnas.1818539116","volume":"116","author":"XJ Chen","year":"2019","unstructured":"Chen, X. J. et al. Homoharringtonine deregulates MYC transcriptional expression by directly binding NF-\u03baB repressing factor.. Proc. Natl. Acad. Sci. U. S. A. 116, 2220\u20132225 (2019).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"49566_CR19","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1158\/1078-0432.CCR-24-1317","volume":"30","author":"MM Lizardo","year":"2024","unstructured":"Lizardo, M. M. et al. Pharmacologic inhibition of EIF4A blocks NRF2 synthesis to prevent osteosarcoma metastasis. Clin. Cancer Res. 30, 4464\u20134481 (2024).","journal-title":"Clin. Cancer Res."},{"key":"49566_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-69171-3","author":"JL Oblinger","year":"2024","unstructured":"Oblinger, J.L., Wang, J., Wetherell, G.D. et al. Anti-tumor effects of the eIF4A inhibitor didesmethylrocaglamide and its derivatives in human and canine osteosarcomas. Sci Rep 14, 19349 (2024). https:\/\/doi.org\/10.1038\/s41598-024-69171-3","journal-title":"Sci. Rep."},{"key":"49566_CR21","doi-asserted-by":"crossref","unstructured":"Thomas, L. R. & Tansey, W. P. Proteolytic Control of the Oncoprotein Transcription Factor Myc. In Advances in Cancer Research. 110 77\u2013106 (Academic Press Inc., 2011).","DOI":"10.1016\/B978-0-12-386469-7.00004-9"},{"key":"49566_CR22","first-page":"2486","volume":"4","author":"SR Hann","year":"1984","unstructured":"Hann, S. R. & Eisenman, R. N. Proteins encoded by the human c-myc oncogene: Differential expression in neoplastic cells. Mol. Cell. Biol. 4, 2486\u20132497 (1984).","journal-title":"Mol. Cell. Biol."},{"key":"49566_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/vco.12192","volume":"15","author":"JS Fowles","year":"2017","unstructured":"Fowles, J. S., Dailey, D. D., Gustafson, D. L., Thamm, D. H. & Duval, D. L. The Flint Animal Cancer Center (FACC) Canine Tumour Cell Line Panel: A resource for veterinary drug discovery, comparative oncology and translational medicine. Vet. Comp. Oncol. 15, 481\u2013492 (2017).","journal-title":"Vet. Comp. Oncol."},{"key":"49566_CR24","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1177\/1040638711408064","volume":"23","author":"LE O\u2019Donoghue","year":"2011","unstructured":"O\u2019Donoghue, L. E., Rivest, J. P. & Duval, D. L. Polymerase chain reaction-based species verification and microsatellite analysis for canine cell line validation. J. Vet. Diagn. Invest. 23, 780\u2013785 (2011).","journal-title":"J. Vet. Diagn. Invest."},{"key":"49566_CR25","doi-asserted-by":"publisher","unstructured":"Farrell, K. B., Das, S., Nordeen, S. K., Lambert, J. R. & Thamm, D. H. VDX-111 targets proliferative pathways in canine cancer cell lines. PLoS One 19(5): e0303470. https:\/\/doi.org\/10.1371\/journal.pone.0303470","DOI":"10.1371\/journal.pone.0303470"},{"key":"49566_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"49566_CR27","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. FeatureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923\u2013930 (2014).","journal-title":"Bioinformatics"},{"key":"49566_CR28","doi-asserted-by":"publisher","unstructured":"Love, M.I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550 (2014). https:\/\/doi.org\/10.1186\/s13059-014-0550-8","DOI":"10.1186\/s13059-014-0550-8"},{"key":"49566_CR29","doi-asserted-by":"crossref","unstructured":"Wu, T. et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation 2:3, https:\/\/doi.org\/10.1016\/j.xinn.2021.100141.(2021).","DOI":"10.1016\/j.xinn.2021.100141"},{"key":"49566_CR30","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"49566_CR31","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1158\/0008-5472.CAN-17-1679","volume":"78","author":"L Garcia-Alonso","year":"2018","unstructured":"Garcia-Alonso, L. et al. Transcription factor activities enhance markers of drug sensitivity in cancer. Cancer Res. 78, 769\u2013780 (2018).","journal-title":"Cancer Res."},{"key":"49566_CR32","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1021\/acs.bioconjchem.1c00507","volume":"32","author":"KB Farrell","year":"2021","unstructured":"Farrell, K. B., Zinnen, S., Thamm, D. H. & Karpeisky, A. Gemcitabine-Ibandronate Conjugate Enables the Bone-Targeted Combination Therapy in Bone Cancer: Synthesis and efficacy in combination with docetaxel. Bioconjug. Chem. 32, 2530\u20132539 (2021).","journal-title":"Bioconjug. Chem."},{"key":"49566_CR33","doi-asserted-by":"publisher","first-page":"W739","DOI":"10.1093\/nar\/gkac382","volume":"50","author":"A Ianevski","year":"2022","unstructured":"Ianevski, A., Giri, A. K. & Aittokallio, T. SynergyFinder 3.0: An interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 50, W739\u2013W743 (2022).","journal-title":"Nucleic Acids Res."},{"key":"49566_CR34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00280-012-1963-2","volume":"71","author":"J Nemunaitis","year":"2013","unstructured":"Nemunaitis, J. et al. Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors. Cancer Chemother. Pharmacol. 71, 35\u201341 (2013).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"49566_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0274383","author":"K Megquier","year":"2022","unstructured":"Megquier K, Turner-Maier J, Morrill K, Li X, Johnson J, et al. (2022) The genomic landscape of canine osteosarcoma cell lines reveals conserved structural complexity and pathway alterations. PLOS ONE 17(9): e0274383. https:\/\/doi.org\/10.1371\/journal.pone.0274383","journal-title":"PLoS One"},{"key":"49566_CR36","unstructured":"Broad DepMap Portal. DepMap Public 25Q2 depmap.org (2025)."},{"key":"49566_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","volume":"25","author":"R Arafeh","year":"2025","unstructured":"Arafeh, R., Shibue, T., Dempster, J. M., Hahn, W. C. & Vazquez, F. The present and future of the Cancer Dependency Map. Nat. Rev. Cancer. 25, 59\u201373 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"49566_CR38","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1038\/sj.onc.1201138","volume":"14","author":"WW Marhin","year":"1997","unstructured":"Marhin, W. W., Chen, S., Facchini, L. M., Fornace, A. J. & Penn, L. Z. Myc represses the growth arrest gene gadd45. Oncogene 14, 2825\u20132834 (1997).","journal-title":"Oncogene"},{"key":"49566_CR39","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1182\/blood.V110.11.4163.4163","volume":"110","author":"A Mohamed-Hadley","year":"2007","unstructured":"Mohamed-Hadley, A., Gibbs, J. D., Liebermann, D. A. & Hoffman, B. Gadd45a behaves as a tumor suppressor and Gadd45b behaves as an oncogene in myc-mediated block in myeloid differentiation. Blood 110, 4163\u20134163 (2007).","journal-title":"Blood"},{"key":"49566_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01433-5","author":"M Pakjoo","year":"2024","unstructured":"Pakjoo, M., Ahmadi, S.E., Zahedi, M. et al. Interplay between proteasome inhibitors and NF-\u03baB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors. Cell Commun Signal 22, 105 (2024). https:\/\/doi.org\/10.1186\/s12964-023-01433-5","journal-title":"Cell Commun. Signal."},{"key":"49566_CR41","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1124\/mol.108.049114","volume":"74","author":"MH Sung","year":"2008","unstructured":"Sung, M. H. et al. Dynamic effect of bortezomib on nuclear factor-\u03baB activity and gene expression in tumor cells. Mol. Pharmacol. 74, 1215\u20131222 (2008).","journal-title":"Mol. Pharmacol."},{"key":"49566_CR42","doi-asserted-by":"publisher","unstructured":"Sogbein, O. et al. Bortezomib in cancer therapy: Mechanisms, side effects, and future proteasome inhibitors. Life Sci.\u00a0358\u00a0(2024). https:\/\/doi.org\/10.1016\/j.lfs.2024.123125","DOI":"10.1016\/j.lfs.2024.123125"},{"key":"49566_CR43","doi-asserted-by":"publisher","unstructured":"Meuten, T. K., Dean, G. A., Thamm, D. H. & Review The PI3K-AKT-mTOR signal transduction pathway in canine cancer. Vet. Pathol.\u00a061, 339\u2013356 (2024). https:\/\/doi.org\/10.1177\/03009858231207021","DOI":"10.1177\/03009858231207021"},{"key":"49566_CR44","doi-asserted-by":"publisher","unstructured":"Pyuen AA, Meuten T, Rose BJ, Thamm DH. In vitro effects of PI3K\/mTOR inhibition in canine hemangiosarcoma. PLOS ONE 13(7): e0200634. (2018) https:\/\/doi.org\/10.1371\/journal.pone.0200634","DOI":"10.1371\/journal.pone.0200634"},{"key":"49566_CR45","doi-asserted-by":"publisher","unstructured":"Li, L. et al. Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma. JCI Insight 6, (2021). https:\/\/doi.org\/10.1172\/jci.insight.138197","DOI":"10.1172\/jci.insight.138197"},{"key":"49566_CR46","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1158\/1541-7786.MCR-24-0444","volume":"23","author":"ZJ Walker","year":"2025","unstructured":"Walker, Z. J. et al. Ribosome profiling reveals translational reprogramming via mTOR activation in omacetaxine-resistant multiple myeloma. Mol. Cancer Res. 23, 611\u2013621 (2025).","journal-title":"Mol. Cancer Res."},{"key":"49566_CR47","doi-asserted-by":"publisher","unstructured":"Zhang J, Chen B, Wu T, Wang Q, Zhuang L, et al. (2015) Synergistic Effect and Molecular Mechanism of Homoharringtonine and Bortezomib on SKM-1 Cell Apoptosis. PLOS ONE 10(11): e0142422. (2015) https:\/\/doi.org\/10.1371\/journal.pone.0142422","DOI":"10.1371\/journal.pone.0142422"},{"key":"49566_CR48","doi-asserted-by":"publisher","unstructured":"Nguyen, T., Parker, R., Zhang, Y. et al. Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms. BMC Cancer 18, 1129 (2018). https:\/\/doi.org\/10.1186\/s12885-018-5018-x","DOI":"10.1186\/s12885-018-5018-x"},{"key":"49566_CR49","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1158\/0008-5472.CAN-20-2720","volume":"81","author":"DS Micalizzi","year":"2021","unstructured":"Micalizzi, D. S., Ebright, R. Y., Haber, D. A. & Maheswaran, S. Translational regulation of cancer metastasis. Cancer Res. 81, 517\u2013524 (2021).","journal-title":"Cancer Res."},{"key":"49566_CR50","doi-asserted-by":"publisher","unstructured":"Lee, L. J. et al. Cancer Plasticity: The Role of mRNA Translation. Trends in Cancer.\u00a07, 134\u2013145 (2021). https:\/\/doi.org\/10.1016\/j.trecan.2020.09.005","DOI":"10.1016\/j.trecan.2020.09.005"},{"key":"49566_CR51","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1126\/science.aay0939","volume":"367","author":"RY Ebright","year":"2020","unstructured":"Ebright, R. Y. et al. Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis. Science 367, 1468 (2020).","journal-title":"Science"},{"key":"49566_CR52","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00277-013-1758-5","volume":"92","author":"W Yu","year":"2013","unstructured":"Yu, W. et al. Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory\/relapsed acute myeloid leukemia: A single-center experience. Ann. Hematol. 92, 1091\u20131100 (2013).","journal-title":"Ann. Hematol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49566-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49566-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49566-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T23:25:19Z","timestamp":1781479519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-49566-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["49566"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-49566-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18442"}}